Kodiak Sciences Inc. (KOD): Operating Income
-$234.39M
Year ended 2025-12-31
-$246.42M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$234.39M | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$186.85M | n/m | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$277.32M | n/m | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | -$341.38M | n/m | 2025-03-27, From 2022-01-01 |
| 2021-12-31 | -$267.05M | n/m | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | -$136.01M | n/m | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | -$49.19M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$26.37M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$25.52M | n/m | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | -$17.15M | n/a | 2019-03-27, From 2016-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | -$234.39M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | -$115.22M | n/m |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | -$110.50M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$208.35M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | -$346.01M | n/m |
| Prokidney Corp. (PROK) | 2025-12-31 | -$165.01M | n/m |
| Replimune Group, Inc. (REPL) | 2026-03-31 | -$319.92M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$147.70M | n/m |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | -$142.90M | n/m |
Compare KOD, CCCC, TSHA, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗